Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA class II histocompatibility antigen DR beta 5 chain (HLA-DRB5) is a beta chain component of the MHC class II molecule, encoded by the HLA-DRB5 gene on chromosome 6. It forms a heterodimer with the alpha chain (HLA-DRA) and is expressed on antigen-presenting cells such as B lymphocytes, dendritic cells, and macrophages. HLA-DRB5 presents extracellular peptides to CD4+ T cells, thereby playing a pivotal role in adaptive immune responses. The region is highly polymorphic, affecting peptide binding and immune specificity; these polymorphisms are key in transplantation biology, autoimmune susceptibility (notably in multiple sclerosis), and adverse drug reactions. HLA-DRB5 is linked to the broader immunogenetic landscape influencing immune response variability, graft compatibility, and disease risk.
Modulation of antigen presentation to CD4+ T cells, altering immune responses. Influencing the repertoire of peptides presented by antigen-presenting cells and the subsequent T cell activation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA class II histocompatibility antigen DR beta 5 chain (HLA-DRB5).